HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a clinical-stage biotechnology company bringing regenerated organs to patients, today reported unaudited financial results for the three months ended March 31, 2015.
Help employers find you! Check out all the jobs and post your resume.
